Clinicopathological features of steroid-refractory immune-mediated hepatotoxicity induced by immune checkpoint inhibitors

Gastrointestinal Cancer

Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Am J Gastroenterol

Hwang SY, Rezaee-Zavareh MS, Attia AM, Kaymen EA, Tran N, Abou-Alfa GK, Parikh ND, Singal AG, Yang JD

doi: 10.14309/ajg.0000000000003546

Gastrointestinal Cancer

Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer

Gut

Yang Z, Xia F, Li J, Jin J, Wang G, Lin G, Li X, Wu A, Zhang T, Zhang W, Xu J, Tao K, Ding P, Li Y, Xu Y, Song Z, Li L, Deng Y, Wan X, Xu RH, Zhang Z, Yao H, Zhang Z, Chinese Society of Colorectal Surgery, CNSCRS, Chinese Society of Colorectal Surgery CNSCRS

doi: 10.1136/gutjnl-2025-336979

Hepatology

Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study

Hepatology

Moeckli B, Wassmer CH, El Hajji S, Kumar R, Rodrigues Ribeiro J, Tabrizian P, Feng H, Schnickel G, Kulkarni AV, Allaire M, Asthana S, Karvellas CJ, Meeberg G, Wei L, Chouik Y, Kumar P, Gartrell R, Martinez M, Kang E, Sogbe M, Sangro B, Schwacha-Eipper B, Schmiderer A, Krendl FJ, Goossens N, Lacotte S, Compagnon P, Toso C

doi: 10.1097/HEP.0000000000001289

RECOMMENDED

Inflammatory Bowel Disease

Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease - an international, multicenter, retrospective cohort study

★ 1 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Clin Gastroenterol Hepatol

Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S, McBride J, Uzzan M, Lukáš M, Fumery M, Nogami A, Kobayashi T, Nancey S, Neves JC, Mendes JM, Wegener BA, Bergereau E, Fernandes R, Kuriakose Kuzhiyanjal AJ, Vieujean S, Spencer A, Baillie S, Estevinho MM, Simão I, O'Neill C, Gututui M, Thompson E, Jama A, Chai N, Pavlidis P, D'Amico F, Limdi J, Magro F, Sebastian S, Digby-Bell J, Parkes GC, Din S, Hart A, Peyrin-Biroulet L, JAKne International Study Group

doi: 10.1016/j.cgh.2025.04.031

COMMENTED

Esophagus Diseases

Eosinophilic esophagitis patients report substantial disease burden comparable to more systemic immune-mediated diseases

★ 3 Recommended and commented by Prof. Dr Stephan Vavricka, Faculty Member

BMC Gastroenterol

Theswet E, Brücker C, Kreienbühl A, Greuter T, Schoepfer AM, Straumann A, Biedermann L

doi: 10.1186/s12876-025-03942-8

COMMENTED

Inflammatory Bowel Disease

Long-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis

★ 3 Recommended and commented by Prof. Dr Stephan Vavricka, Faculty Member

Inflamm Intest Dis

Grob F, Häberling I, Novacek G, Kreienbühl A, Biedermann L, Rogler G, Schreiner P

doi: 10.1159/000546511

Inflammatory Bowel Disease

Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

Lancet Gastroenterol Hepatol

Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ, COSTA Study Group

doi: 10.1016/S2468-1253(25)00291-2

Inflammatory Bowel Disease

Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice

Inflamm Bowel Dis

Gisbert JP, Chaparro M

doi: 10.1093/ibd/izaf273

Inflammatory Bowel Disease

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

Clin Gastroenterol Hepatol

Privitera G, Bezzio C, Figlioli G, D'Amico F, Mendes J, Varca S, Zingone F, Lago IR, Onali S, Caprioli FA, Chaparro M, Acosta MB, Karmiris K, Degabli NT, Dar L, Pastorelli L, Gutiérrez A, Orlando A, Zabana Y, Saibeni S, Piovani D, Savarino EV, Pugliese D, Magro F, Danese S, Armuzzi A, PODIUM Study Group, Bonovas S, Fanizzi F, Ferraz P, Scaldaferri F, Barberio B, Moraleja I, Favale A, Noviello D, Gisbert JP, Porto-Silva M, Psistakis A, Yanai H, Kopylov U, Di Pietro M, Madero-Velázquez L, Macaluso FS, Orlando R, Gabbiadini R, Buono AD, Loy L, Migliorisi G, Zoratti C

doi: 10.1016/j.cgh.2026.01.017

Related content

Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer

Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study

Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease - an international, multicenter, retrospective cohort study

Eosinophilic esophagitis patients report substantial disease burden comparable to more systemic immune-mediated diseases

Long-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis

Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis